Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Relmada Therapeutics, Inc.
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
Business
Jul 27 2021
5 min read

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

- All tested doses of REL-1017, including the maximum tolerated dose, showed a highly statistically significant difference in abuse potential vs. oxycodone with p-values